Background: Anemia is one of the common manageable problem among the pregnant women worldwide, which contributes to maternal and perinatal mortality. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in treating anemia during pregnancy. Objective of this study was to compare safety and efficacy of intravenous ferric carboxymaltose with intravenous ferric sucrose in iron deficiency anemia during pregnancy.Methods: It’s an interventional prospective study conducted in Department of Obstetrics and Gynecology at NIMS, Jaipur, Rajasthan, India constituting of 100 pregnant women. Group 1- 50 pregnant women were treated with intravenous ferric carboxymaltose and Group 2: 50 pregnant women were treated with intravenous iron sucrose. Hemoglobin and serum ferritin levels were measured pre and post treatment with parenteral iron therapy. The efficacy of intravenous ferric carboxymaltose in comparison to intravenous iron sucrose was assessed. The evaluation of safety and tolerance with the parenteral therapy was also performed.Results: Anemia during pregnancy was more prevalent among the reproductive age group and in multiparous women. The mean rise in the hemoglobin level with ferric carboxymaltose was 2.92 gm/dl and with that of iron, sucrose was 1.08 gm/dl. The man rise in the serum ferritin levels with ferric carboxymaltose was 64.97ng/ml and with iron sucrose was 31.64 ng/ml. Ferric carboxymaltose was observed to be safer with no adverse events in comparison to the Iron sucrose which was related with adverse events among 03 pregnant women.Conclusions: Intravenous ferric carboxymaltose was more efficacious and safer in comparison to intravenous iron sucrose among pregnant women. Hence, ferric carboxymaltose is the drug of choice in treatment of iron deficiency anemia during pregnancy.

Background: Pregnancy is the most vulnerable condition prone for anemia (most commonly iron deficiency anemia). Hence requires drug therapy for iron store replenishment. Comparing the safety between ferrous carboxymaltose and iron sucrose therapy in iron deficiency anemia during pregnancy in obstetrics and gynecology ward at a tertiary care hospital. Methods: A prospective observational single centered study was conducted on 60 pregnant women who were diagnosed with iron deficiency anemia in the department of obstetrics and gynecology at tertiary care teaching hospital. The subjects were divided into two groups, first group was administered iron sucrose 200mg and second group was administered ferrous carboxymaltose 500mg. The relative incidence of drug administrative adverse event was low in Ferrous Carboxymaltose than compare to Iron Sucrose. Result: The adverse event occurred in 3.33% for Ferrous Carboxymaltose and 13.33% for Iron Sucrose. The mean rise of hemoglobin was 2.92 g/l for Ferrous Carboxymaltose and 1.08 g/l for iron sucrose. Conclusion: In this study it was found that Ferrous carboxymaltose is safer in comparison to the Iron sucrose among the pregnant women with Iron deficiency anemia.